Pacira Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
BofA/Merrill Lynch Upgrades Pacira Pharmaceuticals (PCRX) to Neutral (Earlier)
July 31, 2015 9:48 AM EDTBofA/Merrill Lynch earlier upgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Underperform to Neutral with a price target of $69.00 (from $70.00).
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $61.80 yesterday.
... MorePacira Pharma (PCRX) Misses Q2 EPS by 1c
July 30, 2015 8:17 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.23, $0.01 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $59.1 million versus the consensus estimate of $62.97 million.
For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.
... More